1. Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. Krebs in Deutschland für 2017/2018. 13 ed2021.
2. Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. New England Journal of Medicine. 2023;388(17):1547-58.
3. Piazza P, Checcucci E, Puliatti S, Belenchòn IR, Veccia A, Rivas JG, et al. The Long but Necessary Journey Towards Optimization of the Cause-Effect Relationship Between Input and Output for Accountable Use of ChatGPT for Academic Purposes. European Urology Focus.
4. Mottet N, Cornford P, van den Bergh R, Briers E, Eberli D, De Meerleer G, et al. EAU - EANM - ESTRO - ESUR - ISUP - SIOG Guidelines on Prostate Cancer. Edn. presented at the EAU Annual Congress Milan 2023.: EAU Guidelines Office, Arnhem, The Netherlands.; 2023 [Available from: http://uroweb.org/guidelines/compilations-of-all-guidelines/.
5. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF). S3-Leitlinie Prostatakarzinom, Langversion 6.2, 2021, AWMF Registernummer: 043/022OL2021.